Australian Pharmaceutical Industries Limited announced revised profit guidance for the financial year ending 31 August 2017, due to a further decline in consumer sentiment and despite the company maintaining retail market share in the period. The company now expects full year net profit after tax to be approximately 5% up on fiscal year 2016. Although trading in retail was weaker than anticipated, API's pharmacy distribution business remains on track to meet expectations for the year and the company also expects reported net debt to be positive before December 2017.